Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability.
about
Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analoguesPromising approaches to circumvent the blood-brain barrier: progress, pitfalls and clinical prospects in brain cancer.Adenosine receptor signaling: a key to opening the blood-brain doorConstraining cyclic peptides to mimic protein structure motifs.Can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions?Pluronic modified leptin with increased systemic circulation, brain uptake and efficacy for treatment of obesity.Strategies to overcome the barrier: use of nanoparticles as carriers and modulators of barrier properties.A brain-sparing diphtheria toxin for chemical genetic ablation of peripheral cell lineages.Endothelial-Monocyte Activating Polypeptide II Suppresses the In Vitro Glioblastoma-Induced Angiogenesis by Inducing Autophagy.Agile delivery of protein therapeutics to CNSAdenosine receptor signaling modulates permeability of the blood-brain barrier.Native pyroglutamation of huwentoxin-IV: a post-translational modification that increases the trapping ability to the sodium channel.Targeting the neurovascular unit for treatment of neurological disorders.Cerebrovascular MRI: a review of state-of-the-art approaches, methods and techniques.Novel treatment strategies for brain tumors and metastases.Efficacy of cabazitaxel in mouse models of pediatric brain tumorsImplementation of a chronic unilateral intraparenchymal drug delivery system in a swine model.CNS drug delivery: opioid peptides and the blood-brain barrierRevolutionary impact of nanodrug delivery on neuroscience.Targeted drug delivery to treat pain and cerebral hypoxiaDesign of peptide and peptidomimetic ligands with novel pharmacological activity profiles.Various drug delivery approaches to the central nervous system.Post-acute brain injury urinary signature: a new resource for molecular diagnostics.C-type natriuretic peptide modulates permeability of the blood-brain barrierMilk protein peptides with angiotensin I-converting enzyme inhibitory (ACEI) activity.Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugs.Anticonvulsant neuropeptides as drug leads for neurological diseases.Shuttle-mediated drug delivery to the brain.The potential role of milk-derived peptides in cardiovascular disease.Nanostructure-based drug delivery systems for brain targeting.Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.Opioid receptor targeting ligands for pain management: a review and update.Impact of physiochemical properties on pharmacokinetics of protein therapeutics.Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches.Neuropeptides: metabolism to bioactive fragments and the pharmacology of their receptors.The blood-brain barrier: structure, function and therapeutic approaches to cross it.Early engineering approaches to improve peptide developability and manufacturability.A peptide derivative serves as a fibroblast growth factor 2 antagonist in human gastric cancer.Enhanced serum proteolysis resistance of cell-penetrating peptides.
P2860
Q24650190-CA07A18F-BF06-4F36-849F-E52AE27564C8Q26778701-9501E05B-B7DE-4F52-8B04-0B411AA298E8Q26795435-14E7CA1E-ED43-4408-9551-F1F1730AF021Q30367509-376F8E86-7838-4332-994A-56B68429F398Q30496929-960F99A9-7ADB-4617-8662-C0E87F378FBDQ30592302-756BB95B-FEE6-47AC-BB3B-F9BCCD8410B5Q30768284-14344484-DF1F-4435-95AB-14F1F69D153EQ30844300-5D491E86-DD6C-4DFA-BCD4-AAE1F900186FQ33847497-EAD2A2F9-3410-4423-9562-235508714240Q34079647-279759B4-B937-4C99-A84B-51A00F258EA8Q34216355-177E295E-A155-464C-AE66-4295AAB2EEC7Q34795674-9B0A4703-DB34-4101-BB92-FC6F67A2F9B1Q34974827-38E0AE20-42B7-4810-9C5A-3B6996034316Q35641545-CBD0CE4A-9417-4CCF-823C-2D1A8A56CEF3Q35734471-B2BE0111-2B78-4D7E-860E-0A9F7C397C84Q35788771-C41D7970-DC19-4EB9-BF90-F0F9CC7FE634Q36045342-3DE7A813-83D0-41FB-8797-1329D024BC64Q36439195-7FDFF48C-D999-41F0-A5CF-F448900494D5Q36460631-14398C62-57AD-48E4-AE91-FFD3D9FB380CQ36591611-EB012367-DF5A-4CE0-A500-79617BFAAE65Q37365405-2F61C928-B6E6-4396-A639-BCC136F8B70FQ37657525-8C607F29-7F96-41D9-8C52-ACE41D0D2B6BQ37667700-46F26E90-32A0-4D9E-A32C-4D1315ED1332Q37695310-F396209B-0E6D-4C1B-A8C4-2C85D176918CQ37725759-A52E434F-30D7-444E-9386-FDDF64973C62Q37834512-BDB3DBE9-9E2E-48AD-9C6D-513A83A33205Q37845684-C4D12E6B-3034-494F-91D1-240EEFC8993FQ37896550-34D9D9FA-3C44-4548-AA49-3504507CC938Q37903711-D22B5CBC-97D0-4589-87BC-F26E34243949Q37939942-BDE86496-DCF7-4674-9088-50B4905ECF2DQ37995554-43888273-8331-41AB-AB82-63CE9FE91244Q38028661-4C6D4186-7EBD-43E8-B629-9BB2DE9558DFQ38098934-C750A905-5037-4C56-B57C-C3AFAC85BE61Q38100704-29AD7B70-A52C-4669-B45D-53534B956745Q38136249-80163066-51A6-4597-881B-0BF38767FF56Q38217456-45F2846C-6ADD-4957-AEE9-14A2464F7B7CQ38232202-71B22399-8DC9-4BE3-98C3-FB1AA4125999Q38262021-907B18C3-7C37-4959-8EED-E8B3979F5041Q38884499-5AD09DE6-248A-4085-9EFA-F3490A3BE26EQ38908688-54E014BA-8AC3-4971-8F35-D880A1BD8945
P2860
Peptide drug modifications to enhance bioavailability and blood-brain barrier permeability.
description
2001 nî lūn-bûn
@nan
2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Peptide drug modifications to ...... od-brain barrier permeability.
@ast
Peptide drug modifications to ...... od-brain barrier permeability.
@en
Peptide drug modifications to ...... od-brain barrier permeability.
@nl
type
label
Peptide drug modifications to ...... od-brain barrier permeability.
@ast
Peptide drug modifications to ...... od-brain barrier permeability.
@en
Peptide drug modifications to ...... od-brain barrier permeability.
@nl
prefLabel
Peptide drug modifications to ...... od-brain barrier permeability.
@ast
Peptide drug modifications to ...... od-brain barrier permeability.
@en
Peptide drug modifications to ...... od-brain barrier permeability.
@nl
P2093
P1433
P1476
Peptide drug modifications to ...... ood-brain barrier permeability
@en
P2093
R D Egleton
T J Gillespie
P304
P356
10.1016/S0196-9781(01)00537-X
P577
2001-12-01T00:00:00Z